Creative Biolabs Advances Antibody Research With Integrated ADCC and ADCP Functional Assays

Creative Biolabs today announced commercially available, fully integrated ADCC and ADCP that assess how an antibody engages immune mechanisms and thus guide the rational design of candidate therapeutic antibodies.
New York, USA - August 20, 2025 - During the antibody development timeline, understanding functional efficacy remains an indispensable milestone for characterizing therapeutic promise. Antibody performance, whether in oncology or autoimmunity, ultimately hinges on which in vivo signals become amplified. The most telling effector routes are antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), both of which Creative Biolabs now quantifies with increased precision and safety.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

Creative Biolabs' ADCC functional assay [https://adcc.creative-biolabs.com/adcc-assay-services.htm] service is based on advanced reporter gene systems, avoiding the safety risks associated with traditional radioactive methods. Supporting multiple cell types-NK, macrophages, or neutrophils-the assay allows flexible customization according to client needs, enabling researchers to rapidly obtain highly informative data.

However, observing only ADCC often cannot fully capture the antibody's true effector function. After binding to target cells, antibodies may also recruit phagocytic cells such as macrophages to clear targets through engulfment and degradation-a mechanism at the core of ADCP. Creative Biolabs' ADCP assay [https://adcc.creative-biolabs.com/adcp-assay-services.htm] uses optimized detection systems and sensitive signal capture to quantitatively measure the antibody's ability to trigger phagocytosis. Importantly, this service accounts for differences among cell types and antibody subclasses, providing evaluation results that closely reflect in vivo conditions.

"In antibody development, ADCC and ADCP are not competing mechanisms but complementary forces," noted an immunology expert from Creative Biolabs.

Especially in cancer immunotherapy, any single mechanism alone often fails to prevent tumor growth and metastasis, yet antibodies with combined mechanisms demonstrate anti-tumor efficacy. Creative Biolabs' expertise and accumulated experience in ADCC and ADCP assays provide a powerful toolset to support this process.

Quality and reproducibility remain the foundation on which the company bases its productivity and its reputation. All assays run under a dual-layer framework of standard operating procedures and continuous quality assessment, while bespoke validations range from genetic verification and reporter gene readouts to cross-validation with other functional assays. This flexible and systematic approach has positioned Creative Biolabs as a trusted partner for many pharmaceutical companies and research institutions.

Complete assay summaries, user protocols, and technical consultations are available at https://adcc.creative-biolabs.com.

About Creative Biolabs

Creative Biolabs will continue expanding its technological platforms and expert team to provide comprehensive support for global antibody research and development, accelerating the emergence of more clinically valuable molecules.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=creative-biolabs-advances-antibody-research-with-integrated-adcc-and-adcp-functional-assays]
Phone: 1-631-830-6441
Country: United States
Website: https://adcc.creative-biolabs.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.